Truist raises target for Labcorp stock to USD 365.00

Truist Financial raised its Labcorp stock price target from USD 350.00 to USD 365.00 on September 21, 2026, while maintaining a Buy rating, according to MarketBeat. The move keeps the target above the latest NYSE reference of USD 308.11 dated September 30, 2026.

Target moves above current quote

The revised target is one of the clearest current analyst signals for Labcorp. MarketBeat reported that nine of twelve analysts carried Buy ratings, while three maintained Hold ratings, producing a Moderate Buy consensus and an average target of USD 337.73.

The USD 365.00 target is USD 56.89 above the USD 308.11 NYSE reference, a difference of 18.46 percent based on those two values. The target change itself was USD 15.00, or 4.29 percent above the previous USD 350.00 target.

Second-quarter growth supports outlook

Labcorp generated USD 3.73 billion in revenue in the second quarter of 2026, up 5.80 percent from the second quarter of 2025, according to Fortune. Adjusted earnings per share rose 14.90 percent to USD 4.99, and adjusted operating margin expanded 70 basis points to 15.80 percent.

The same second-quarter 2026 call described Diagnostics revenue of USD 2.90 billion, up 5.50 percent year over year, and Biopharma Laboratory Services revenue of USD 836.00 million, up 6.50 percent. Labcorp also raised its full-year 2026 adjusted earnings per share guidance to USD 18.10-18.55 and its enterprise revenue growth outlook to 5.40-6.30 percent.

Results date sets the next test

Labcorp's next scheduled report is October 28, 2026, according to Yahoo Finance. That release will show whether the second-quarter pattern of revenue growth, margin expansion and higher adjusted earnings per share carried into the third quarter.

NYSE valuation and business scale

Labcorp was last quoted at USD 308.11 on the NYSE on September 30, 2026 at 4:00 p.m. ET. Its market capitalization was USD 25.3 billion, while the 52-week range stood at USD 244.52 to USD 341.80 on the same market-data snapshot.

The company provides diagnostic laboratory services and biopharma laboratory services. Its investor-relations page identifies Labcorp as a global life sciences company listed on the NYSE under ticker LH and cites 71,000 full-time employees.